- Conditions
- Menopause Hot Flashes
- Interventions
- Placebo, Fezolinetant
- Drug
- Lead sponsor
- Rebecca Thurston
- Other
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–15
of 15
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent, Prostate Carcinoma, Prostate Neoplasm, Prostate Adenocarcinoma, Prostate Cancer With Bone Metastasis, Vasomotor Disturbance, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Vasomotor Symptoms; Hot Flashes, Androgen Deprivation Therapy, Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma, Androgen-deprivation Therapy, Hot Flashes, Hot Flushes, Hot Flushes and/or Sweats
- Interventions
- fezolinetant - reference formulation, Placebo
- Drug
- Lead sponsor
- Shehzad Basaria, M.D.
- Other
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Menopause, Hot Flashes
- Interventions
- Fezolinetant, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 51
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 46 more
- Conditions
- Healthy Volunteers, Renal Impairment
- Interventions
- fezolinetant
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 7
- States / cities
- Garden Grove, California • Rialto, California • Clearwater, Florida + 4 more
- Conditions
- Healthy Subjects
- Interventions
- Fezolinetant
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hot Flashes
- Interventions
- fezolinetant, placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 72
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Ensley, Alabama + 62 more
- Conditions
- Hot Flashes
- Interventions
- fezolinetant, placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 1,831 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 142
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Ensley, Alabama + 108 more
- Conditions
- Healthy Volunteers
- Interventions
- fezolinetant - test formulation, fezolinetant - reference formulation
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Localized Breast Carcinoma
- Interventions
- Biospecimen Collection, Fezolinetant, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Other
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Prostate CA, Androgen Deprivation Therapy
- Interventions
- Fezolinetant
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Hepatic Impairment, Healthy Volunteers
- Interventions
- fezolinetant
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 4
- States / cities
- Clearwater, Florida • Miami, Florida • Orlando, Florida + 1 more
- Conditions
- Hot Flashes
- Interventions
- Fezolinetant, placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 65
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 53 more
- Conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Interventions
- Fezolinetant, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Columbus, Ohio
- Conditions
- Hot Flashes
- Interventions
- Fezolinetant, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 40 Years to 75 Years · Female only
- Enrollment
- 999 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Lomita, California + 39 more
- Conditions
- Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular
- Interventions
- Metformin, semaglutide, Anti-hypertensives, Lipid Lowering Medication, Life style intervention, Fezolinetant, Hormonal therapy
- Drug · Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 45 Years to 55 Years · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Chapel Hill, North Carolina • Richmond, Virginia